Speakers
- Subir Basak, PhD, MBA, Chief Executive Officer, Celestial Biologicals, Chief Commercial Officer, Intas Biopharmaceuticals
- Mark Bowditch, Patent Attorney, Sandoz
- Crawford Brown, PhD, Chief Executive Officer, Eden Biodesign, a member of The Watson Group
- Gillian Cannon, MBA, PhD, Commercial Head, Merck Bioventures
- Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals USA , Inc.
- Charles Di Liberti, President, Montclair Bioequivalence Services, LLC
- Janis K. Fraser, Ph.D, Principal, Fish & Richardson
- Steven E. Goldberg, MD, MBA, VP & Chief of Medical Affairs, Express Scripts
- Brian Harvey, Vice President of Regulatory Affairs, Sanofi-Aventis
- Priscilla Huang, Finance Lead, Merck Bioventures
- Shefali Kakar, PhD, Clinical Pharmacology, Oncology Business Unit, Novartis Pharmaceuticals Corporation
- Kristie C. Kuhl, JD, Senior Vice President, Makovsky
- Bruce Leicher, Senior Vice President and General Counsel, Momenta Pharmaceuticals Inc.
- Magdalena Leszczyniecka, PhD, MBA, President and CEO, STC Biologics
- M.S. Mahadevan, Director, Strategic Marketing, Process Solutions Business Unit, EMD Millipore
- Curtis Meuse, Research Chemist, National Institute of Standards and Technology (NIST)
- D. Christopher Ohly, Partner, Schiff Hardin LLP
- Naomi Pearce, IP Director and Counsel, Hospira
- Peter J. Pitts, President, Center for Medicine in the Public Interest
- Suzanne M. Sensabaugh, MS, MBA, Founder & Member, HartmannWillner LLC
- S. Thippeswamy, MD, President and CEO, Dr. Swamy's Lab
- Kevin Whelan, Director of Biologics Policy, Pfizer
- Gillian Woollett, MD, Chief Scientist, Engel & Novitt
- Zheru Zhang, PhD, Vice President of Research and Development, Celltrion